Nanoparticles News and Research

RSS

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

University of Missouri leaders celebrated a nanomedicine milestone today as they announced the creation of a new drug development company. The new company forms a partnership between university researchers and an international pharmaceutical firm to advance testing of a potential cancer treatment created at MU.

3 Dec 2010

Argonne researchers awarded 65 million hours of computing time on Blue Gene/P supercomputer

Four researchers at the U.S. Department of Energy's (DOE) Argonne National Laboratory lead projects that have been awarded a total of 65 million hours of computing time on Argonne's energy-efficient Blue Gene/P ("Intrepid") supercomputer. The researchers will conduct advanced simulation and analysis, performing virtual experiments that would be almost impossible and impractical in the natural world. They will also develop scalable system software needed to fully harness the power of supercomputers.

2 Dec 2010

Scientists discover a new method to produce gold nanoparticles

Gold nanoparticles, tiny pieces of gold so small that they can't be seen by the naked eye, are used in electronics, healthcare products and as pharmaceuticals to fight cancer. Despite their positive uses, the process to make the nanoparticles requires dangerous and extremely toxic chemicals. While the nanotechnology industry is expected to produce large quantities of nanoparticles in the near future, researchers have been worried about the environmental impact of the global nanotechnological revolution.

30 Nov 2010

Magnetic fluid hyperthermia destroys cells inside tumors

Magnetic fluid hyperthermia (MFH) is a promising new cancer treatment that essentially "fries" cells inside tumors. The procedure has been used successfully in prostate, liver, and breast tumors.

24 Nov 2010

USPTO, EPO issue key patents for Tekmira's LNP technology

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).

23 Nov 2010

New method to target and destroy cancerous cells using hyperthermia

Using hyperthermia, Virginia Tech engineering researchers and a colleague from India unveiled a new method to target and destroy cancerous cells. The research was presented at the 63rd annual meeting of the American Physical Society Nov. 23 in Long Beach, Calif.

23 Nov 2010

Researchers unveil new method to target and destroy cancerous cells

23 Nov 2010

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company's senior executives presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, ongoing in Berlin, Germany.

19 Nov 2010

Nanoparticles in everyday products can affect lungs: Study

Tiny particles used in a range of everyday products from computers to shampoo can adversely affect the lungs in very different ways, a study has shown.

18 Nov 2010

Access Pharmaceuticals to present two oncology posters at CPR Conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.

18 Nov 2010

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

16 Nov 2010

TU/e researchers image stages of calcification process in atherosclerosis

Atherosclerosis is characterized by hardening and thickening of artery walls, with serious health consequences. Researchers at Eindhoven University of Technology (TU/e) have imaged the stages in the calcification process at a nanometer scale.

15 Nov 2010

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

A vaginal gel that affords both contraception and HIV protection using nanoparticles that carry bee venom is one of the bold, unconventional ideas that won a 2010 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation.

10 Nov 2010

Innovative method for in-cell gene manipulation

A cross-disciplinary Small Medicine and Advanced Research Translation (SMART) team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University (NCKU), Tainan, Taiwan, has announced a breakthrough in the precision in-cell gene scission at pre-designed sequence sites using Artificial Targeting Light Activated Nano Scissors (ATLANS) and a custom build photonic device.

9 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

New nanoparticle deodorant has antibacterial and anti-odor properties

Scientists are reporting development of a new approach for dealing with offensive household and other odors one that doesn't simply mask odors like today's room fresheners, but eliminates them at the source. Their research found that a deodorant made from nanoparticles hundreds of times smaller than peach fuzz eliminates odors up to twice as effectively as today's gold standard.

30 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

The Methodist Hospital Research Institute® (TMHRI) today opened a 12-story, 440,000 square foot research facility dedicated solely to research and equipped with the world's most advanced technology to help research scientists, physicians and engineers cure diseases that afflict today's patients.

28 Oct 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010